Links Between Cognitive Deficits During Normal or Pathological Aging and Slow Waves Measured in EEG

NCT06501495 · tracked via the Priya Life Science France tracker

Sponsor

Assistance Publique - Hôpitaux de Paris

Phase

Not applicable

Started

2025-04-24

Last updated

2026-04-13

Condition(s) studied

AgingAlzheimer Disease

Investigational drug(s) / intervention(s)

video polysomnographyAttention task

video polysomnography: video polysomnography during 2 nights

Attention task: Attention task : SART Test (Sustained Attention to Response Task)

Study summary

With age, memory processes (encoding, consolidation and retrieval) as well as daytime vigilance are altered. Sleep is also impaired in older adults, notably slow waves that are known to play a key role in memory consolidation. Interestingly, some slow waves can also be detected in EEG recordings during wakefulness, and have been related to vigilance fluctuations.

The investigators believe that slow waves, during both sleep and wakefulness, could constitute a common biomarker of sleep disturbances and daytime vigilance problems. A dysregulation of slow waves could thus explain the impact of aging on the different memory processes. Since alterations in memory capacity, attention, and sleep quality are further exacerbated in patients with Alzheimer's disease (AD), the investigators propose to study the links between aging (normal and pathological), sleep and daytime vigilance alterations, and their impacts on the different key stages of memory.

The investigators will examine the associations between slow waves and changes in memory and vigilance in normal and pathological aging by studying young adults, seniors without cognitive disorders, and patients with prodromal AD. By replaying sensory cues associated with learning material during sleep, the investigators will also evaluate the effectiveness of auditory stimulation during sleep to enhance memory consolidation in older adults without and without cognitive deficits.

Overall, this study aims to better understand the relationships between slow waves, aging, memory, and vigilance, providing insights into cognitive decline and potential interventions in aging and Alzheimer's disease.

Eligibility

Sex

ALL

Min age

18 Years

Max age

85 Years

Healthy volunteers

Accepted

* Common Inclusion Criteria for All Three Groups: Male or female Signed informed consent Affiliated with a social security system Native French speakers Completed at least 7 years of schooling (minimum 9th grade level) Specific Inclusion Criteria for Each Group: Patients: Age: 60 to 85 years Prodromal stage of Alzheimer's disease diagnosed according to international diagnostic criteria, characterized by a clinical phenotype of progressive amnesic syndrome of the hippocampal type, associated with biological markers of Alzheimer's disease 1) from lumbar puncture (Aβ \< 600 pg/mL and ptau \> 60 pg/mL)or 2) amyloid PET (positron emission tomography), or 3) with positive plasma Alzheimer's biomarkers Cognitively Healthy Seniors: Age: 60 to 85 years Age and sex matched with the Patients group "Cognitively healthy" status defined by a score of ≥ 26 on the MMSE (Mini-Mental State Examination), a score of ≥ 16 on the BREF (Batterie Rapide d'Efficience Frontale), and a score of ≥ 8 on the 5-word test Young Adults: Age: 18 to 35 years Sex matched with the Patients group "Cognitively healthy" status defined by a score of ≥ 26 on the MMSE (Mini-Mental State Examination), a score of ≥ 16 on the BREF (Batterie Rapide d'Efficience Frontale), and a score of ≥ 8 on the 5-word test

Primary outcome measure(s)

slow waves density — 2 days
quantifying slow waves with their density (during sleep, wakefulness at rest and during tasks)

Trial sites (1)

Facility	City	Region	Status
Maladies du Sommeil	Paris	France	Recruiting

More Assistance Publique - Hôpitaux de Paris trials in France

Transpulmonary Pressure - Guided Mechanical Ventilation in Morbidly Obese ARDS Patients: a Feasibility Study. Recruiting

AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium Active, not recruiting

Population Pharmacokinetics of Anti-infectives in Critically Ill Children Recruiting

Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF) Active, not recruiting

Searching Biomarkers of Acute Intestinal Ischemic Injuries Recruiting

Other trials for the same condition

Diagnostic and Prognostic Value of New Quick Tests of Action Slowing in Stroke and in Cognitive Neurodegenerative Disease Recruiting

Diagnostic Evaluation of Dementia with Lewy Bodies Using a Multimodal Approach Recruiting

Effect of CAFfeine on Cognition in Alzheimer's Disease Recruiting

Safety of a Strategy Combining Etanercept Administration With Repeated Contrast Ultrasound in Patients With Alzheimer's Disease Recruiting

Aging Well Together - 'Getting to Know You Better': Characterization of Health FACTors in People Advancing in AGE Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06501495 on ClinicalTrials.gov ↗ ← All trials in France